BD PharmingenTM Purified Mouse Anti-Human IL-8

Description

Expression of IL-8 by stimulated CD14+ human monocytes. Human PBMC were stimulated for 6 hours with LPS 10 ng/ml final concentration in the presence of GolgiStop 2 muM final concentration; Cat. No. 554724 . The PBMC were harvested, stained with FITC-mouse anti-human CD14 antibody FITC-M5E2, Cat. No. 555397 , fixed, permeabilized, and subsequently stained with 0.25 mug of PE-mouse anti-human IL-8 antibody PE-G265-8, Cat. No. 554720 following the BD Pharmingen staining protocol left panel . The data reflect gating on monocytes, based on forward and side scattered light signals. To demonstrate specificity of staining, the binding of PE-G265-8 was blocked by the preincubation of the conjugated antibody with recombinant human IL-8 0.25 mug, Cat. No. 554609; center panel , and by preincubation of the fixed/permeabilized cells with unlabelled G265-8 antibody 2.5 mug, Cat. No. 554717; right panel prior to staining with the PE-G265-8 antibody. The quadrant markers for the bivariate dot plots were set based on the autofluorescence control, and verified with the recombinant cytokine blocking center panel and unlabelled antibody right panel blocking specificity controls. Expression of IL-8 by stimulated CD14+ human monocytes. Human PBMC were stimulated for 6 hours with LPS 10 ng/ml final concentration in the presence of GolgiStop 2 muM final concentration; Cat. No. 554724 . The PBMC were harvested, stained with FITC-mouse anti-human CD14 antibody FITC-M5E2, Cat. No. 555397 , fixed, permeabilized, and subsequently stained with 0.25 mug of PE-mouse anti-human IL-8 antibody PE-G265-8, Cat. No. 554720 following the BD Pharmingen staining protocol left panel . The data reflect gating on monocytes, based on forward and side scattered light signals. To demonstrate specificity of staining, the binding of PE-G265-8 was blocked by the preincubation of the conjugated antibody with recombinant human IL-8 0.25 mug, Cat. No. 554609; center panel , and by preincubation of the fixed/permeabilized cells with unlabelled G265-8 antibody 2.5 mug, Cat. No. 554717; right panel prior to staining with the PE-G265-8 antibody. The quadrant markers for the bivariate dot plots were set based on the autofluorescence control, and verified with the recombinant cytokine blocking center panel and unlabelled antibody right panel blocking specificity controls. Expression of IL-8 by stimulated CD14+ human monocytes. Human PBMC were stimulated for 6 hours with LPS 10 ng/ml final concentration in the presence of GolgiStop 2 muM final concentration; Cat. No. 554724 . The PBMC were harvested, stained with FITC-mouse anti-human CD14 antibody FITC-M5E2, Cat. No. 555397 , fixed, permeabilized, and subsequently stained with 0.25 mug of PE-mouse anti-human IL-8 antibody PE-G265-8, Cat. No. 554720 following the BD Pharmingen staining protocol left panel . The data reflect gating on monocytes, based on forward and side scattered light signals. To demonstrate specificity of staining, the binding of PE-G265-8 was blocked by the preincubation of the conjugated antibody with recombinant human IL-8 0.25 mug, Cat. No. 554609; center panel , and by preincubation of the fixed/permeabilized cells with unlabelled G265-8 antibody 2.5 mug, Cat. No. 554717; right panel prior to staining with the PE-G265-8 antibody. The quadrant markers for the bivariate dot plots were set based on the autofluorescence control, and verified with the recombinant cytokine blocking center panel and unlabelled antibody right panel blocking specificity controls. Show More Expression of IL-8 by stimulated CD14+ human monocytes. Human PBMC were stimulated for 6 hours with LPS 10 ng/ml final concentration in the presence of GolgiStop 2 muM final concentration; Cat. No. 554724 . The PBMC were harvested, stained with FITC-mouse anti-human CD14 antibody FITC-M5E2, Cat. No. 555397 , fixed, permeabilized, and subsequently stained with 0.25 mug of PE-mouse anti-human IL-8 antibody PE-G265-8, Cat. No. 554720 following the BD Pharmingen staining protocol left panel . The data reflect gating on monocytes, based on forward and side scattered light signals. To demonstrate specificity of staining, the binding of PE-G265-8 was blocked by the preincubation of the conjugated antibody with recombinant human IL-8 0.25 mug, Cat. No. 554609; center panel , and by preincubation of the fixed/permeabilized cells with unlabelled G265-8 antibody 2.5 mug, Cat. No. 554717; right panel prior to staining with the PE-G265-8 antibody. The quadrant markers for the bivariate dot plots were set based on the autofluorescence control, and verified with the recombinant cytokine blocking center panel and unlabelled antibody right panel blocking specificity controls. Show More Expression of IL-8 by stimulated CD14+ human monocytes. Human PBMC were stimulated for 6 hours with LPS 10 ng/ml final concentration in the presence of GolgiStop 2 muM final concentration; Cat. No. 554724 . The PBMC were harvested, stained with FITC-mouse anti-human CD14 antibody FITC-M5E2, Cat. No. 555397 , fixed, permeabilized, and subsequently stained with 0.25 mug of PE-mouse anti-human IL-8 antibody PE-G265-8, Cat. No. 554720 following the BD Pharmingen staining protocol left panel . The data reflect gating on monocytes, based on forward and side scattered light signals. To demonstrate specificity of staining, the binding of PE-G265-8 was blocked by the preincubation of the conjugated antibody with recombinant human IL-8 0.25 mug, Cat. No. 554609; center panel , and by preincubation of the fixed/permeabilized cells with unlabelled G265-8 antibody 2.5 mug, Cat. No. 554717; right panel prior to staining with the PE-G265-8 antibody. The quadrant markers for the bivariate dot plots were set based on the autofluorescence control, and verified with the recombinant cytokine blocking center panel and unlabelled antibody right panel blocking specificity controls. Expression of IL-8 by stimulated CD14+ human monocytes. Human PBMC were stimulated for 6 hours with LPS 10 ng/ml final concentration in the presence of GolgiStop 2 muM final concentration; Cat. No. 554724 . The PBMC were harvested, stained with FITC-mouse anti-human CD14 antibody FITC-M5E2, Cat. No. 555397 , fixed, permeabilized, and subsequently stained with 0.25 mug of PE-mouse anti-human IL-8 antibody PE-G265-8, Cat. No. 554720 following the BD Pharmingen staining protocol left panel . The data reflect gating on monocytes, based on forward and side scattered light signals. To demonstrate specificity of staining, the binding of PE-G265-8 was blocked by the preincubation of the conjugated antibody with recombinant human IL-8 0.25 mug, Cat. No. 554609; center panel , and by preincubation of the fixed/permeabilized cells with unlabelled G265-8 antibody 2.5 mug, Cat. No. 554717; right panel prior to staining with the PE-G265-8 antibody. The quadrant markers for the bivariate dot plots were set based on the autofluorescence control, and verified with the recombinant cytokine blocking center panel and unlabelled antibody right panel blocking specificity controls.